FibroBiologics Inc. Common Stock (FBLG)

FairStock Score: 40/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings, honest accounting, and a margin of safety. FibroBiologics has none of the first two yet. It is a clinical-stage biotechnology company with 15 employees and several fibroblast-based programs, including CYMS101, which completed Phase 1 for multiple sclerosis, and CYWC628, which completed preclinical work for wound healing. But the filed figures show no revenue in any period. In fiscal 2025, the year ended 2025-12-31, it lost $18.6 million, or $0.42 per diluted share. Fiscal 2024, the year ended 2024-12-31, lost $11.2 million, and fiscal 2023, the year ended 2023-12-31, lost $16.5 million. More recently, in fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $5.0 million, and in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $4.1 million. Those are not earnings that can support a moat. Financial health is poor. Trailing free cash flow is negative $14.8 million, a FairStock calculation, against a $6.4 million market cap at the 2026-10-13 close of $0.96. That makes the FCF yield -231.5%. The Piotroski F-Score is 2/9 and Altman Z-Score is -9.46, both FairStock calculations, signaling distress. P/B is 1.26, so book value is not irrelevant, but cash burn can erode it quickly. The computed Lynch category is none, because the company lost money in each of the last four years. The price may look cheap at under $1, but without revenue, profits, or positive cash flow, it is a speculative option on clinical success, not a Graham-style bargain. Growth is currently measured in larger losses, not profits. I would watch cash, dilution, and trial data, not the share price alone.

In plain English: FibroBiologics is a tiny drug developer with 15 employees. It has no revenue and has lost money every year, including $18.6 million in fiscal 2025, the year ended 2025-12-31. At 96 cents a share, the price is hard to judge by profits because there are none; it looks speculative, not a proven bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer